Promed Laboratories Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 1.68 Cr
as on 17-12-2024
- Company Age 53 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 17.96 Cr
as on 17-12-2024
- Revenue -99.99%
(FY 2022)
- Profit -1330.93%
(FY 2022)
- Ebitda -28.42%
(FY 2022)
- Net Worth -21.55%
(FY 2022)
- Total Assets -11.37%
(FY 2022)
About Promed Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.68 Cr.
The company has closed loans amounting to ₹17.96 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pankaj Badlani, Mahesh Badlani, and Subhash Rijhwani serve as directors at the Company.
- CIN/LLPIN
U85195MP1971PTC001100
- Company No.
001100
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jul 1971
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Promed Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subhash Rijhwani  | Director | 02-Mar-1994 | Current |
| Pankaj Badlani | Director | 01-Sep-2003 | Current |
| Mahesh Badlani | Director | 02-Mar-1994 | Current |
Financial of Promed Laboratories.
Promed Laboratories Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 99.99% decrease. The company also saw a substantial fall in profitability, with a 1330.93% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Promed Laboratories?
In 2022, Promed Laboratories had a public holding of 28.98%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pure Pharma LimitedActive 44 years 4 monthsPankaj Badlani, Mahesh Badlani and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Sep 2016 | ₹3.75 Cr | Satisfied |
Bank Of Baroda Creation Date: 06 Sep 2005 | ₹8.30 Cr | Satisfied |
Bank Of Baroda Creation Date: 28 Jul 2005 | ₹5.91 Cr | Satisfied |
How Many Employees Work at Promed Laboratories?
Promed Laboratories has a workforce of 3 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Promed Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Promed Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
